AhmannD. L.BiselH. F.HahnR. G.: Phase II Clinical Trial of Isophosphamide (NSC-109724) in Patients with Advanced Breast Cancer, Cancer Chemother. Rep.58: 861–865 (Nov.-Dec.) 1974.
2.
KovachJ. S.SchuttA. J.HahnR. G.: A Phase II Study of Intermittent High Dose Isophosphamide Therapy of Advanced Colorectal Cancer, Oncology29: 34–39 (1) 1974.
3.
CostanziJ. J.GaglianoR.LoukasD.: Ifosfamide in the Treatment of Recurrent or Disseminated Lung Cancer, Cancer41: 1715–1719 (May) 1978.
4.
FalksonG.FalksonH. C.: Further Experience With Isophosphamide, Cancer Treat. Rep.60: 955–957 (July) 1976.
5.
RodriguezV.BodeyG. P.FreireichE. J.: Reduction of Ifosfamide Toxicity Using Dose Fractionation, Cancer Res.36: 2945–2948 (Aug.) 1976.
6.
BremnerD. N.McCormickJ. S.ThompsonJ. W. W.: Clinical Trial of Isophosphamide (NSC-109724) — Results and Side Effects, Cancer Chemother. Rep.58: 889–893 (Nov./Dec.) 1974.
7.
RodriguezV.McCredieK. B.KeatingM. J.: Isophosphamide Therapy for Hematologic Malignancies in Patients Refractory to Prior Treatment, Cancer Treat. Rep.62: 493–497 (Apr.) 1978.
8.
NelsonR. L.CreavenP. J.CohenM. H.: Phase I Clinical Trial of a Three-Day Divided Dose Schedule of Ifosfamide (NCS-109724), Eur. J. Cancer12: 195–198 (Mar.) 1976.
9.
vanDykJ. J.FalksonH. C.vander MerweA. M.: Unexpected Toxicity in Patients Treated with Iphosphamide, Cancer Res.32: 921–924 (May) 1972.
10.
HandelsmanH.GoldsmithM. A.SlavikM.: Isophosphamide Clinical Brochure, National Cancer Institute, Bethesda, Maryland, 1974.
11.
AllenL. M.CreavenP. J.: In Vitro Activation of Isophosphamide (NSC-109724) A New Oxazaphosphorine, by Rat Liver Microsomes, Cancer Chemother. Rep.56: 603–610 (Oct.) 1972.
12.
HillD. L.LasterW. R.KirkM. C.: Metabolism of Isophosphamide [2-(2-chloroethyIamino)-3-(2-chloroethyl) tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide] and Production of a Toxic Iphosphamide Metabolite, Cancer Res.33: 1016–1022 (May) 1973.
13.
ConnorsT. A.CoxP. J.FarmerP. B.: Some Studies of the Active Intermediates Formed in the Microsomal Metabolism of Cyclophosphamide and Isophosphamide, Biochem. Pharmacol.23: 115–129 (Jan.) 1974.
14.
AlarconR. A.MeienhoferJ.AthertonE.: Isophosphamide as a New Acrolein-Producing Antineoplastic Isomer of Cyclophosphamide, Cancer Res.32: 2519–2523 (Nov.) 1972.
CreavenP. J.AllenL. M.CohenM. H.: Studies on the Clinical Pharmacology and Toxicology of Isophosphamide (NSC-109724), Cancer Treat. Rep.60: 445–449 (Apr.) 1976.
20.
CohenM. H.CreavenP. J.TejadaF.: Phase I Trial of Isophosphamide (NSC-109724), Cancer Chemother. Rep.59: 751–755 (July/Aug.) 1975.
21.
DeFronzoR. A.AbeloffM.BraineH.: Renal Dysfunction After Treatment with Isophosphamide (NSC-109724), Cancer Chemother. Rep.58: 375–382 (May/June) 1974.
22.
WassermanT. H.: The Nitrosoureas: An Outline of Clinical Schedules and Toxic Effects, Cancer Treat. Rep.60: 709–711 (June) 1976.
23.
CostanzaM. E.NathansonL.SchoenfeldD.: Results with Methyl-CCNU and DTIC in Metastatic Melanoma, Cancer40: 1010–1015 (Sept.) 1977.
24.
EvansA. E.BernsteinI.FinkelsteinJ.: Methyl-CCNU for Patients with Previously Treated Metastatic Neuroblastoma — a Phase II Study, Cancer Treat. Rep.61: 83–85 (Jan./Feb.) 1977.
25.
EngstromP. F.CatalanoR. B.CreechR. H.: Phase II Study of Methyl-CCNU (NSC-95441) in Advanced Gastrointestinal Cancer, Cancer Treat. Rep.60: 285–287 (Mar.) 1976.
26.
CedermarkB. J.DidolkarM. S.EliasE. G.: Methyl-CCNU (NSC-95441) in Advanced Colorectal Carcinoma after Failure of 5-Fluorouracil (NSC-19893) Therapy, Cancer Treat. Rep.60: 235–238 (Mar.) 1976.
27.
RossiA.RivaA.BonadonnaG.: Methyl-CCNU (NSC-95441) Versus Methyl-CCNU plus Cyclophosphamide (NSC-26271) in Advanced Gastrointestinal Cancer, Cancer Chemother. Rep.59: 1161–1162 (Nov./Dec.) 1975.
28.
AhmannD. L.HahnK. G.BiselH. F.: Evaluation of 1-(2-chloroethyl)-3(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU, NSC-95441) Versus Combined Imidazole Carboxamide (NSC-45388) and Vincristine (NSC-67574) in Palliation of Disseminated Malignant Melanoma, Cancer33: 615–618 (Mar.) 1974.
29.
AhmannD. L.BiselH. F.HahnR. G.: A Phase II Evaluation of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (NSC-95441) in Patients with Advanced Breast Cancer, Cancer Res.34: 27–30 (Jan.) 1974.
30.
TranumB. L.HautA.RivkinS.: A Phase II Study of Methyl-CCNU in the Treatment of Solid Tumors and Lymphomas: A Southwest Oncology Group Study, Cancer35: 1148–1153 (Apr.) 1975.
31.
MauriceP.GlidewellO.JacquillatC.: Comparison of Methyl-CCNU and CCNU in Patients with Advanced Forms of Hodgkin's Disease, Lymphosarcoma and Reticulum Cell Sarcoma, Cancer41: 1658–1663 (May) 1978.
32.
PoseyL. E.MorganL. R.: Methyl-CCNU Versus Methyl-CCNU and 5-Fluorouracil in Carcinoma of the Large Bowel, Cancer Treat. Rep.61: 1453–1458 (Nov.) 1977.
33.
RichardsF.CooperM. R.MussH. B.: Methyl-CCNU, Alone and in Combination with Vincristine, or Vincristine and Methotrexate, in Advanced Bronchogenic Carcinoma, Cancer38: 1077–1082 (Sept.) 1976.
34.
TornyosK.SilbermanH.SolomonA.: Phase II Study of Oral Methyl-CCNU and Prednisone in Previously Treated Alkylating Agent-Resistant Multiple Myeloma, Cancer Treat. Rep.61: 785–787 (Aug.) 1977.
35.
YoungR. C.CanellosG. P.ChabnerB. A.: Treatment of Malignant Melanoma with Methyl CCNU, Clin. Pharmacol. Ther.15: 617–622 (June) 1974.
36.
BakerL. H.TalleyR. W.MatterR.: Phase III Comparison of the Treatment of Advanced Gastrointestinal Cancer with Bolus Weekly 5-FU Vs. Methyl-CCNU plus Bolus Weekly 5-FU, Cancer38: 1–7 (July) 1976.
37.
AhmannD. L.HahnR. G.BiselH. F.: Comparative Study of Methyl-CCNU (NSC-95441) with Cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) with Vincristine (NSC-67574) in Patients with Disseminated Malignant Melanoma, Cancer Chemother. Rep.59: 451–453 (Mar./Apr.) 1975.
38.
LivingstonR. B.EinhornL. H.BodeyG. P.: COMB (Cyclophosphamide, Oncovin, Methyl-CCNU and Bleomycin): A Four-Drug Combination in Solid Tumors, Cancer36: 327–332 (Aug.) 1975.
MoertelC. G.ShuttA. J.HahnR. G.: Therapy of Advanced Colorectal Cancer with a Combination of 5-Fluorouracil, methyl-1, 3-cis (2-chloroethyl)-1-nitrosourea, and Vincristine, J. Natl. Cancer Inst.54: 69–71 (Jan.) 1975.
41.
MoertelC. G.ShuttA. J.ReitemeierR. J.: Therapy for Gastrointestinal Cancer with Nitrosoureas Alone and in Drug Combination, Cancer Treat. Rep.60: 729–732 (June) 1976.
42.
WassermanT. H.SlavikM.CarterS. K.: Clinical Comparison of the Nitrosoureas, Cancer36: 1258–1268 (Oct.) 1975.
43.
WassermanT. H.SlavikM.CarterS. K.: Methyl-CCNU in Clinical Cancer Therapy, Cancer Treat. Rev.1: 251–269 (Dec.) 1974.
44.
BonoV. H.: Review of Mechanism of Action Studies of the Nitrosoureas, Cancer Treat. Rep.60: 699–702 (June) 1976.
45.
WheelerG. P.BowdonB. S.GrimsleyJ. A.: Interrelationships of Some Chemical, Physiochemical and Biological Activities of Several 1-(2-haloethyl)-1-nitrosoureas, Cancer Res.34: 194–200 (Jan.) 1974.
46.
OliverioV. T.: Pharmacology of the Nitrosoureas: An Overview, Cancer Treat. Rep.60: 703–707 (June) 1976.
47.
SponzoR. W.DeVitaV. T.OliverioV. T.: Physiologic Disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU) in Man, Cancer31: 1154–1159 (May) 1973.
48.
LeeW.MooreR. P.WamplerG. L.: Interstitial Pulmonary Fibrosis as a Complication of Prolonged Methyl-CCNU Therapy, Cancer Treat. Rep.62: 1355–1358 (Sept.) 1978.
